Big liiiinnee!!, page-10

Both solutions require hardware. However, it can reasonably be assumed the initial target markets for MEB & RAP already have smart phones. So rap doesn’t require ‘an extra purchase’.
IMO the cash burn is playing a role however this is beginning to be offset by MEB’s recent positive progress with great trial results, FDA submission, and commercial contracts being executed. This places them 3-6mths ahead of RAP imo who are awaiting trial results this month. The next item for a MEB rerate is FDA approval, or a partnership with an insurance company that the CEO has hinted. Or even a strategic partnership with a blue chip looking to expand in the med tech area such as Apple or Samsung. They both sell the range of hardware required for this tech so they could provide synergies. The large tech blue chips are aggressively looking at growth opportunities beyond hardware now.  High margin, unique, scalable, solutions such as these two will be on their radar.

https://www.irishtimes.com/business...investment-plan-to-underpin-profits-1.3589823